January 22, 2025 07:30 AM EST
R&D

J&J’s Spra­va­to hit $1B in rev­enue in 2024

Max Bayer

Pharma Reporter

John­son & John­son’s bur­geon­ing de­pres­sion treat­ment Spra­va­to eclipsed $1 bil­lion in rev­enue in 2024 as the phar­ma’s neu­ro­science pipeline comes in­to view.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

GLP-1s can cut the risk of Alzheimer’s. What does that mean for No­vo Nordisk?

Chi­na's biotech boom is threat­en­ing US drug­mak­er­s' dom­i­nance

US with­draw­al from WHO could jeop­ar­dize in­for­ma­tion shar­ing

In­hi­brx’s ear­ly col­orec­tal can­cer da­ta cloud­ed by pa­tient death

On­col­o­gy biotech Ar­riVent does an­oth­er Chi­na ADC deal, this time with Lepu Bio­phar­ma

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times